Literature DB >> 17156343

T lymphocytes expressing CCR3 are increased in allergic rhinitis compared with non-allergic controls and following allergen immunotherapy.

J N Francis1, C M Lloyd, I Sabroe, S R Durham, S J Till.   

Abstract

BACKGROUND: In T cell-associated allergic inflammation, homing of T-helper 2 (Th2) effector cells to mucosal sites may be influenced by chemokine receptor expression. Previous studies have identified CCR3 and CCR4 as putative markers of Th2 cells and CCR5 and CXCR3 as markers of Th1 cells. The aim of this study was to assess differential chemokine receptor expression from symptomatic atopic grass pollen-sensitive subjects, compared with patients on high-dose allergen injection immunotherapy (IT) and healthy controls.
METHODS: We examined chemokine receptor expression (CCR1-7 and CXCR1-4) by flow cytometry of peripheral blood CD4+ and CD8+ T cells. We also depleted peripheral blood mononuclear cell (PBMC) populations of CCR3+ CD4+ cells by magnetic bead separation and cells were stimulated with grass pollen allergen for 6 days. Cytokine production was measured by enzyme-linked immunosorbent assay.
RESULTS: On freshly isolated PBMC, atopic individuals exhibited increased numbers of CCR3+ CD4+ cells compared with normal controls (P < 0.01). CCR3 expression in IT patients was reduced compared with matched atopic rhinitic controls (P < 0.05) and comparable with that observed in normal subjects. Depletion of CCR3+ CD4+ cells from allergen-stimulated PBMC cultures resulted in decreased interleukin (IL)-5 production compared with whole CD4+ populations (P < 0.05). Freshly isolated CCR3+ CD4+ cells have significantly higher intracellular IL-4 and lower IFN-gamma levels than CCR3- CD4+ cells. CD4+ T cells cultured from both peripheral cells and nasal biopsies demonstrated increased expression of CCR3 in the presence of IL-4 (P < 0.05).
CONCLUSION: CCR3+ CD4+ T cells are increased in allergic rhinitis, are reduced by allergen IT, have a Th2 phenotype and contribute to allergen-specific responses. Strategies against CCR3+ T cells may be effective in human allergic diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17156343      PMCID: PMC3385351          DOI: 10.1111/j.1398-9995.2006.01253.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  28 in total

Review 1.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

2.  Expression of chemokine receptors by lung T cells from normal and asthmatic subjects.

Authors:  J J Campbell; C E Brightling; F A Symon; S Qin; K E Murphy; M Hodge; D P Andrew; L Wu; E C Butcher; A J Wardlaw
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

3.  Increased circulating CCR3+ type 2 helper T cells in house dust mite-sensitive Chinese patients with allergic diseases.

Authors:  Chrong-Reen Wang; Pei-Chih Chen; Ming-Fei Liu
Journal:  Asian Pac J Allergy Immunol       Date:  2003-12       Impact factor: 2.310

4.  Systemic chemokine and chemokine receptor responses are divergent in allergic versus non-allergic humans.

Authors:  J Darren Campbell; Monique J Stinson; F Estelle R Simons; Kent T HayGlass
Journal:  Int Immunol       Date:  2002-11       Impact factor: 4.823

5.  Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.

Authors:  Petra A Wachholz; Kayhan T Nouri-Aria; Duncan R Wilson; Samantha M Walker; Adrienne Verhoef; Stephen J Till; Stephen R Durham
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

6.  The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics.

Authors:  P Panina-Bordignon; A Papi; M Mariani; P Di Lucia; G Casoni; C Bellettato; C Buonsanti; D Miotto; C Mapp; A Villa; G Arrigoni; L M Fabbri; F Sinigaglia
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness.

Authors:  Alison A Humbles; Bao Lu; Daniel S Friend; Shoji Okinaga; Jose Lora; Amal Al-Garawi; Thomas R Martin; Norma P Gerard; Craig Gerard
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

8.  CXCR1+CD4+ T cells in human allergic disease.

Authors:  James N Francis; Mikila R Jacobson; Clare M Lloyd; Ian Sabroe; Stephen R Durham; Stephen J Till
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

9.  T cell phenotypes of the normal nasal mucosa: induction of Th2 cytokines and CCR3 expression by IL-4.

Authors:  S Till; L Jopling; P Wachholz; R Robson; S Qin; D Andrew; L Wu; J van Neerven; T Williams; S Durham; I Sabroe
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

10.  CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.

Authors:  C M Lloyd; T Delaney; T Nguyen; J Tian; C Martinez-A; A J Coyle; J C Gutierrez-Ramos
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  10 in total

1.  Increased gene expression of inflammatory markers in nasal turbinate of patients with persistent allergic rhinitis and chronic obstruction.

Authors:  Lucila de Campos; Clóvis Eduardo Santos Galvão; Eliane Conti Mairena; Richard Voegels; Jorge Kalil; Fábio Morato Castro; Edécio Cunha-Neto
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-30       Impact factor: 2.503

2.  Expression of the inflammatory chemokines CCL2, CCL5 and CXCL2 and the receptors CCR1-3 and CXCR2 in T lymphocytes from mammary tumor-bearing mice.

Authors:  Jennifer L Owen; Michael F Criscitiello; Stephania Libreros; Ramon Garcia-Areas; Kathleen Guthrie; Marta Torroella-Kouri; Vijaya Iragavarapu-Charyulu
Journal:  Cell Immunol       Date:  2011-05-10       Impact factor: 4.868

3.  A role for CCL28-CCR3 in T-cell homing to the human upper airway mucosa.

Authors:  E Danilova; I Skrindo; E Gran; B J Hales; W A Smith; J Jahnsen; F E Johansen; F L Jahnsen; E S Baekkevold
Journal:  Mucosal Immunol       Date:  2014-06-11       Impact factor: 7.313

4.  Eosinophils Do Not Drive Acute Muscle Pathology in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Albert C Sek; Ian N Moore; Margery G Smelkinson; Katherine Pak; Mahnaz Minai; Roberta Smith; Michelle Ma; Caroline M Percopo; Helene F Rosenberg
Journal:  J Immunol       Date:  2019-05-29       Impact factor: 5.422

5.  CC chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses.

Authors:  G Banfield; H Watanabe; G Scadding; M R Jacobson; S J Till; D A Hall; D S Robinson; C M Lloyd; K T Nouri-Aria; S R Durham
Journal:  Allergy       Date:  2010-02-10       Impact factor: 13.146

6.  Elevated CCR6+ CD4+ T lymphocytes in tissue compared with blood and induction of CCL20 during the asthmatic late response.

Authors:  J N Francis; I Sabroe; C M Lloyd; S R Durham; S J Till
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

7.  CD8 chemokine receptors in chronic obstructive pulmonary disease.

Authors:  L J C Smyth; C Starkey; F S Gordon; J Vestbo; D Singh
Journal:  Clin Exp Immunol       Date:  2008-08-22       Impact factor: 4.330

Review 8.  The impact of allergen exposure and specific immunotherapy on circulating blood cells in allergic rhinitis.

Authors:  Galateja Jordakieva; Erika Jensen-Jarolim
Journal:  World Allergy Organ J       Date:  2018-08-15       Impact factor: 4.084

9.  Blockade of CC Chemokine Receptor Type 3 Diminishes Pain and Enhances Opioid Analgesic Potency in a Model of Neuropathic Pain.

Authors:  Katarzyna Pawlik; Agata Ciechanowska; Katarzyna Ciapała; Ewelina Rojewska; Wioletta Makuch; Joanna Mika
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

10.  Immunogenic Properties of MVs Containing Structural Hantaviral Proteins: An Original Study.

Authors:  Layaly Shkair; Ekaterina Evgenevna Garanina; Ekaterina Vladimirovna Martynova; Alena Igorevna Kolesnikova; Svetlana Sergeevna Arkhipova; Angelina Andreevna Titova; Albert Anatolevich Rizvanov; Svetlana Francevna Khaiboullina
Journal:  Pharmaceutics       Date:  2022-01-01       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.